Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.





Our Experts


UPMC Media Relations

​UPMC Study Finds That Postmenopausal Estrogen Use is Associated with Improved Survival in Women with Congestive Heart Failure

PITTSBURGH, November 9, 1998 — A study by cardiologists at the University of Pittsburgh Medical Center (UPMC) has found that postmenopausal women with congestive heart failure (CHF) have a lower mortality rate if they are on estrogen therapy.

The study is being presented Nov. 9 at the American Heart Association’s 71st Scientific Session in Dallas by Steven Reis, M.D., assistant professor of medicine at the University of Pittsburgh School of Medicine, director of the LHAS (Ladies Hospital Aid Society) Women’s Heart Center, and co-director of the Magee Women, Infant, and Fetal Heart Program.

"Postmenopausal women with congestive heart failure have a substantially worse prognosis than young women. The purpose of our study was to determine whether post-menopausal estrogen use is beneficial in women who have symptomatic CHF," said Dr. Reis.

The study included 1,362 women with symptomatic CHF enrolled in three U.S. clinical trials involving vesnarinone, a drug for treating heart failure. Of these, 869 women were postmenopausal but were not using estrogen, 210 were post-menopausal estrogen users and 283 were premenopausal.

The study found that the mortality rate after 12 months was 27.6 percent for the first group of women, 16.4 percent for the second group and 11.6 percent for the premenopausal group.

"The use of estrogen was independently associated with decreased mortality," reported Dr. Reis. "Our study suggests that in CHF, premenopausal women and postmenopausal estrogen users have a lower mortality than postmenopausal women who do not use estrogen.

"Although the cellular and molecular mechanism for these findings have not been defined, our results indicate that endogenous and exogenous estrogen is associated with a survival benefit among women with symptomatic CHF independent of age, vesnarinone use and CHF severity," Dr. Reis added.

Please visit the University of Pittsburgh Medical Center's Cardiovascular Institute website for more information on cardiology services and programs.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |